Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the effect of the dose concentration and
administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size
when administered by posterior juxtascleral depot (PJD) every 3 months (AA 15 mg) or 6 months
(AA 15 mg, AA 30 mg) in patients with exudative age-related macular degeneration (AMD).